Plasticity of disseminating cancer cells in patients with epithelial malignancies.
Standard
Plasticity of disseminating cancer cells in patients with epithelial malignancies. / Bednarz, Natalia; Alix-Panabières, Catherine; Pantel, Klaus.
In: CANCER METAST REV, Vol. 31, No. 3-4, 3-4, 2012, p. 673-687.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Plasticity of disseminating cancer cells in patients with epithelial malignancies.
AU - Bednarz, Natalia
AU - Alix-Panabières, Catherine
AU - Pantel, Klaus
PY - 2012
Y1 - 2012
N2 - Current models suggest that at a certain but yet undefined time point of tumour development malignant cells with an aggressive phenotype start to disseminate via the blood stream into distant organs. This invasive phenotype appears to be associated with an epithelial-mesenchymal transition (EMT), which enables detachment of tumour cells from a primary site and migration. The reverse process of mesenchymal-epithelial transition (MET) might play a crucial role in the further steps of metastasis when circulating tumour cells (CTCs) settle down in distant organs and establish (micro-)metastasis. Nevertheless, the exact mechanisms and interplay of EMT and MET are only partially understood and their relevance in cancer patients is unclear. Research groups have just started to apply EMT-related markers in their studies on CTCs in cancer patients. In the present review, we summarize and discuss the current state of investigations on CTCs in the context of research on EMT/MET.
AB - Current models suggest that at a certain but yet undefined time point of tumour development malignant cells with an aggressive phenotype start to disseminate via the blood stream into distant organs. This invasive phenotype appears to be associated with an epithelial-mesenchymal transition (EMT), which enables detachment of tumour cells from a primary site and migration. The reverse process of mesenchymal-epithelial transition (MET) might play a crucial role in the further steps of metastasis when circulating tumour cells (CTCs) settle down in distant organs and establish (micro-)metastasis. Nevertheless, the exact mechanisms and interplay of EMT and MET are only partially understood and their relevance in cancer patients is unclear. Research groups have just started to apply EMT-related markers in their studies on CTCs in cancer patients. In the present review, we summarize and discuss the current state of investigations on CTCs in the context of research on EMT/MET.
KW - Animals
KW - Humans
KW - Biological Markers
KW - Neoplasm Micrometastasis
KW - Neoplastic Cells, Circulating/pathology
KW - Epithelial-Mesenchymal Transition
KW - Neoplasms, Glandular and Epithelial/pathology
KW - Animals
KW - Humans
KW - Biological Markers
KW - Neoplasm Micrometastasis
KW - Neoplastic Cells, Circulating/pathology
KW - Epithelial-Mesenchymal Transition
KW - Neoplasms, Glandular and Epithelial/pathology
M3 - SCORING: Journal article
VL - 31
SP - 673
EP - 687
JO - CANCER METAST REV
JF - CANCER METAST REV
SN - 0167-7659
IS - 3-4
M1 - 3-4
ER -